On CROI were presented the latest data of the effectiveness and safety of fostemsavir
On CROI were presented the latest information on studies of fostemsavir, a drug for the treatment of HIV infection of a fundamentally new type. Fostemsavir (FTR) is the first in its class prodrug of the Temsavir attachment inhibitor (TMR). TMR binds to HIV-1 by blocking the gp120 protein, by which the virus binds to the CD4 receptor and coreceptor located on the surface of T-lymphocytes and prevents cell infection.
15 三月 2019 08:41
One in six South Africans has potential viral resistance to ART
At the Conference on Retroviruses and Opportunistic Infections (CROI2019), was announced that up to 17% of South African people who had not previously been treated and who had evaded testing for HIV could have a drug-resistant strain of the virus, and more ...
更多
14 三月 2019 08:37
MK-8591 implant has been shown to be highly effective at low dosages
#Merck's nucleoside reverse transcriptase translocation inhibitor (NRTTI) MK-8591 (outside the US and Canada - MSD) showed high antiviral activity against HIV-1 with a single dose of 0.5 mg, follows from preliminary results of clinical phase II trials (NCT03272347) ...
更多
U=U运动 (#UequalsU)
我的生活+在东欧和中亚地区组织的信息和教育活动 "U=U" （“无法检测到等于不可传播”，#UnqualsU，#НравноН）旨在传达一个信息，即HIV阳性者在病毒载量无法被检测到时，不能将病毒通过性行为传染给另一个人。
许多研究表明，在血清不一致的夫妇中，HIV阳性伴侣接受ARV治疗并保持无法检测到的病毒载量，则没有HIV性传播病例的发生。
我们的合作伙伴
